Literature DB >> 20460094

Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010.

O Wichmann1, P Stocker, G Poggensee, D Altmann, D Walter, W Hellenbrand, G Krause, T Eckmanns.   

Abstract

During the 2009 influenza pandemic, a monovalent AS03-adjuvanted vaccine was almost exclusively used in Germany for immunisation against the 2009 pandemic influenza A(H1N1) virus. One-dose vaccination was recommended for all age groups. We applied the screening method for the rapid assessment of vaccine effectiveness (VE) based on reported data of vaccinated and unvaccinated pandemic influenza cases and vaccination coverage estimates. Preliminary results demonstrate excellent VE in persons aged 14-59 years (96.8%; 95% confidence interval (CI): 95.2-97.9) and moderately high VE in those 60 years or older (83.3%; 95% CI: 71.0-90.5).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20460094

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  39 in total

1.  Pandemic and seasonal vaccine coverage and effectiveness during the 2009-2010 pandemic influenza in an Italian adult population.

Authors:  Simona Costanzo; Francesco Gianfagna; Mariarosaria Persichillo; Francesca De Lucia; Francesca D Lucia; Angelita Verna; Modjenar Djidingar; Sara Magnacca; Francesca Bracone; Marco Olivieri; Maria Benedetta Donati; Giovanni de Gaetano; Licia Iacoviello
Journal:  Int J Public Health       Date:  2012-02-28       Impact factor: 3.380

2.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

3.  Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.

Authors:  Bernardo Rafael Guzmán Herrador; Preben Aavitsland; Berit Feiring; Marianne A Riise Bergsaker; Katrine Borgen
Journal:  BMC Infect Dis       Date:  2012-03-20       Impact factor: 3.090

4.  Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China.

Authors:  Peng Yang; Li Zhang; Weixian Shi; Guilan Lu; Shujuan Cui; Xiaomin Peng; Daitao Zhang; Yimeng Liu; Huijie Liang; Xinghuo Pang; Quanyi Wang
Journal:  Influenza Other Respir Viruses       Date:  2011-12-30       Impact factor: 4.380

5.  School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program.

Authors:  Ricardo Basurto-Dávila; Martin I Meltzer; Dora A Mills; Garrett R Beeler Asay; Bo-Hyun Cho; Samuel B Graitcer; Nancy L Dube; Mark G Thompson; Suchita A Patel; Samuel K Peasah; Jill M Ferdinands; Paul Gargiullo; Mark Messonnier; David K Shay
Journal:  Health Serv Res       Date:  2017-12       Impact factor: 3.402

6.  Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.

Authors:  Kwok-Hung Chan; Kelvin K W To; Ivan F N Hung; Anna J X Zhang; Jasper F W Chan; Vincent C C Cheng; Herman Tse; Xiao-Yan Che; Honglin Chen; Kwok-Yung Yuen
Journal:  Clin Vaccine Immunol       Date:  2011-03-16

7.  We should not be complacent about our population-based public health response to the first influenza pandemic of the 21st century.

Authors:  Heath A Kelly; Patricia C Priest; Geoffry N Mercer; Gary K Dowse
Journal:  BMC Public Health       Date:  2011-02-03       Impact factor: 3.295

Review 8.  Reflections on pandemic (H1N1) 2009 and the international response.

Authors:  Gabriel M Leung; Angus Nicoll
Journal:  PLoS Med       Date:  2010-10-05       Impact factor: 11.069

9.  Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans.

Authors:  Matthew E Wise; Melissa Viray; James J Sejvar; Paige Lewis; Andrew L Baughman; Walter Connor; Richard Danila; Greg P Giambrone; Christa Hale; Brenna C Hogan; James I Meek; Rendi Murphree; John Y Oh; Arthur Reingold; Norisse Tellman; Susan M Conner; James A Singleton; Peng-Jun Lu; Frank DeStefano; Scott K Fridkin; Claudia Vellozzi; Oliver W Morgan
Journal:  Am J Epidemiol       Date:  2012-05-11       Impact factor: 4.897

10.  Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV-infected patients in the Cologne-Bonn cohort.

Authors:  B Steffens; T Kümmerle; S Koch; A Birtel; C Schwarze-Zander; J Emmelkamp; W V Kern; C Hertenstein; C Wyen; C Lehmann; O A Cornely; J Rockstroh; Gerd Fätkenheuer
Journal:  Eur J Med Res       Date:  2011-07-25       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.